Article Text

Download PDFPDF
Pulmonary actinomycosis complicating infliximab therapy for Crohn’s disease
  1. R D Cohen,
  2. W R Bowie,
  3. R Enns,
  4. J Flint,
  5. J M Fitzgerald
  1. Departments of Medicine and Pathology, University of British Columbia, Vancouver, Canada
  1. Dr Richard Cohen, Room 11223, Gordon & Leslie Diamond Health Care Centre, 11th Floor, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada; richardcohen{at}


The use of anti-tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn’s disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell-mediated immunity, the most frequent being tuberculosis. We report the first case of pulmonary actinomycosis in a patient receiving regular infusions of infliximab, an anti-TNF agent, for Crohn’s disease.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • Abbreviations:
    Crohn’s disease
    tumour necrosis factor
    white blood cells